Key Developments: St. Jude Medical Inc (STJ)

STJ on New York Consolidated

60.47USD
24 Oct 2014
Price Change (% chg)

$0.45 (+0.75%)
Prev Close
$60.02
Open
$60.23
Day's High
$60.48
Day's Low
$59.82
Volume
1,385,665
Avg. Vol
1,683,712
52-wk High
$71.90
52-wk Low
$54.80

Search Stocks

Latest Key Developments (Source: Significant Developments)

St. Jude Medical Inc announces fourth quarter dividend
Tuesday, 21 Oct 2014 05:11pm EDT 

St. Jude Medical Inc:Declares fourth quarter dividend of $0.27 per common share.Dividend is payable Jan. 30, 2015, to shareholders of record on Dec. 31, 2014.  Full Article

St. Jude Medical Inc gives Q4 2014 EPS outlook; revenue outlook below analysts' estimates; lowers FY 2014 revenue outlook; narrows FY 2014 EPS outlook to a range in line with analysts' estimates
Wednesday, 15 Oct 2014 07:30am EDT 

St. Jude Medical Inc:Expects Q4 2014 revenue to be in the range of $1.385 - $1.465 bln.Expects Q4 2014 consolidated adjusted net earnings to be in the range of $1.02 to $1.04 per share.Expects FY 2014 total revenue to be in the range of $5.568 - $5.648 bln.Expects FY 2014 consolidated adjusted net earnings to now be in the range of $3.97 to $3.99.Q4 2014 revenue of $1.493 bln, EPS of $1.04 - Thomson Reuters I/B/E/S.FY 2014 revenue of $5.688 bln, EPS of $3.98 - Thomson Reuters I/B/E/S.  Full Article

St. Jude Medical Inc's CardioMEMS data shows pulmonary artery pressure monitoring significantly reduces heart failure hospitalizations in patients with chronic kidney disease
Monday, 15 Sep 2014 08:30pm EDT 

St. Jude Medical Inc:Announces new data analysis from CHAMPION clinical trial that evaluated outcomes in subgroup of patients with renal dysfunction (kidney failure).CHAMPION trial looked at safety and effectiveness of CardioMEMS HF System for patients with New York Heart Association (NYHA) Class III heart failure (HF) who had been hospitalized for HF in previous 12 months.CardioMEMS system uses miniaturized, wireless monitoring sensor that is implanted in pulmonary artery (PA) during minimally invasive procedure to directly measure PA pressure.Measuring PA pressure allows clinicians to proactively manage treatment for patients with worsening HF before visible symptoms, such as weight and blood pressure changes, occur.System allows patients to transmit PA pressure data from their homes to their health care providers, who then manage appropriate medication changes to reduce likelihood of hospitalization.  Full Article

St. Jude Medical Inc announces launch of OPTISTM Integrated System
Monday, 15 Sep 2014 08:00am EDT 

St. Jude Medical Inc:Secured CE Mark and FDA clearance for new OPTISTM Integrated System.Approval of OPTIS Integrated system marks launch of world`s first PCI optimization system to offer OCT and angiography co-registration.OPTIS Integrated system also integrates St. Jude Medical PressureWire fractional flow reserve (FFR) measurement technology to provide access to critical hemodynamic information during PCI.System will be on display for first time during Transcatheter Cardiovascular Therapeutics (TCT) 2014, in Washington, D C.  Full Article

St. Jude Medical Inc announces two year data from FAME 2 trial shows sustained benefits of FFR-Guided PCI over medical treatment in patients with stable
Tuesday, 2 Sep 2014 09:55am EDT 

St. Jude Medical Inc:Says primary outcome two-year data from the FAME 2 Trial which demonstrated sustained superiority with FFR-guided PCI using St. Jude Medical PressureWireTM technology in patients with stable coronary artery disease (CAD) compared to standard medical therapy alone.Data were published online in The New England Journal of Medicine (NEJM) and presented during hot line late-breaking session at European Society of Cardiology Congress 2014.Results of FAME 2 show patients with stable CAD who received FFR-guided PCI using drug-eluting stents and medical therapy (PCI+MT) had reduced rates of death, myocardial infarction (MI) or urgent revascularization compared to patients who received medical therapy (MT) alone.In particular, in patients who had at least one significant coronary blockage with an FFR value ≤0.80, FFR-guided PCI+MT reduced urgent revascularization by 77 percent compared to medical therapy alone.  Full Article

St. Jude Medical Inc completes acquisition of NeuroTherm
Thursday, 7 Aug 2014 08:00am EDT 

St. Jude Medical Inc:Completes acquisition of privately held NeuroTherm, Inc., amanufacturer of interventional pain management therapies.  Full Article

St. Jude Medical Inc announces third quarter dividend
Tuesday, 29 Jul 2014 06:16pm EDT 

St. Jude Medical Inc:Declares third quarter dividend of $0.27 per common share.This dividend amount is equal to dividend paid during first and second quarters of 2014 and brings total dividend declared for year to $0.81 per share.Payable Oct. 31, 2014, to shareholders of record on Sept. 30, 2014.  Full Article

St. Jude Medical Inc announces CE Mark approval and first use of FlexAbility Ablation Catheter
Tuesday, 22 Jul 2014 08:00am EDT 

St. Jude Medical Inc:Says CE Mark approval and first use of FlexAbility Ablation Catheter, novel ablation technology used by electrophysiologists for the treatment of cardiac arrhythmias.Designed with feedback from physician thought-leaders around world, FlexAbility catheter combines a unique, irrigated flexible catheter tip with a state-of-the-art handle and catheter design.Next-generation flexible tip technology was designed to reduce complications associated with ablation procedures through ability to bend and conform to cardiac anatomy, decreasing amount of pressure distributed to patient's heart wall while simultaneously increasing the stability of therapy delivery.European approval of FlexAbility ablation catheter further strengthens St. Jude Medical's fast-growing ablation technology portfolio.  Full Article

St. Jude Medical Inc gives Q3 2014 outlook below analysts' estimates; raises FY 2014 EPS outlook; raises low end of prior FY 2014 revenue outlook to a range in line with analysts' estimates
Wednesday, 16 Jul 2014 07:30am EDT 

St. Jude Medical Inc:Expects Q3 2014 revenue to be in the range of $1.315 -$1.395 bln.Expects Q3 2014 adjusted net earnings to be in the range of $0.95 to $0.97 per share.Expects FY 2014 revenue to be in the range of $5.640 -$5.760 bln.Expects FY 2014 adjusted net earnings to be in the range of $3.96 to $4.01.Q3 2014 revenue of $1.439 bln, EPS of $1.00 - Thomson Reuters I/B/E/S.FY 2014 revenue of $5.702 bln, EPS of $3.99 - Thomson Reuters I/B/E/S.  Full Article

St. Jude Medical Inc announces definitive agreement to acquire NeuroTherm
Monday, 14 Jul 2014 09:00am EDT 

St. Jude Medical Inc:SignS definitive agreement to acquire privately held NeuroTherm, Inc., manufacturer of interventional pain management therapies.Says for about $200 mln in cash.  Full Article

CORRECTED-UPDATE 2-St. Jude Medical lowers forecast; shares fall

(Corrects low end of pvs revenue forecast and U.S. pacemaker and defibrillator growth in 4th and 9th paragraphs)

Search Stocks